Schwartz Investment Counsel Inc. Has $27.79 Million Stock Holdings in Haemonetics Corporation $HAE

Schwartz Investment Counsel Inc. cut its stake in Haemonetics Corporation (NYSE:HAE) by 0.5% in the 2nd quarter, Holdings Channel.com reports. The fund owned 372,500 shares of the medical instruments supplier’s stock after selling 2,000 shares during the quarter. Schwartz Investment Counsel Inc.’s holdings in Haemonetics were worth $27,792,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in HAE. Citigroup Inc. raised its holdings in Haemonetics by 87.3% in the 1st quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier’s stock valued at $39,755,000 after acquiring an additional 291,574 shares in the last quarter. MetLife Investment Management LLC raised its holdings in Haemonetics by 448.0% in the 1st quarter. MetLife Investment Management LLC now owns 316,542 shares of the medical instruments supplier’s stock valued at $20,116,000 after acquiring an additional 258,776 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Haemonetics by 20.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 966,167 shares of the medical instruments supplier’s stock valued at $60,888,000 after acquiring an additional 165,118 shares in the last quarter. Nuveen LLC acquired a new position in Haemonetics in the 1st quarter valued at $10,340,000. Finally, AQR Capital Management LLC raised its holdings in Haemonetics by 591.6% in the 1st quarter. AQR Capital Management LLC now owns 174,565 shares of the medical instruments supplier’s stock valued at $10,931,000 after acquiring an additional 149,325 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Citigroup dropped their price objective on Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, October 7th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $62.00 price target (down previously from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Robert W. Baird started coverage on Haemonetics in a research note on Thursday, June 26th. They issued an “outperform” rating and a $87.00 price target on the stock. Raymond James Financial lowered Haemonetics from a “strong-buy” rating to an “outperform” rating and decreased their price target for the company from $105.00 to $78.00 in a research note on Monday, August 11th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Haemonetics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $75.89.

Haemonetics Stock Up 0.9%

HAE stock opened at $50.70 on Tuesday. The stock’s 50 day simple moving average is $51.85 and its 200 day simple moving average is $62.63. Haemonetics Corporation has a fifty-two week low of $47.31 and a fifty-two week high of $94.99. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72. The company has a market cap of $2.44 billion, a P/E ratio of 15.50, a price-to-earnings-growth ratio of 0.93 and a beta of 0.37.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.09. The business had revenue of $321.39 million for the quarter, compared to the consensus estimate of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The firm’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.02 EPS. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, research analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.